

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

November 21, 2017

Bruce Cousins Chief Financial Officer Arbutus Biopharma Corporation 100-8900 Glenlyon Parkway Burnaby, British Columbia V5J 5J8

> Re: Arbutus Biopharma Corporation Revised Preliminary Proxy Statement on Schedule 14A Filed November 21, 2017 File No. 001-34949

Dear Mr. Cousins:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence by the staff.

Division of Corporation Finance Office of Healthcare & Insurance

cc: Daniel M. Miller